

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



美瑞健康国际产业集团
Meilleure Health International Industry Group

MEILLEURE HEALTH INTERNATIONAL INDUSTRY GROUP LIMITED

美瑞健康國際產業集團有限公司

(Incorporated in Bermuda with limited liability)

(Stock code: 2327)

POLL RESULTS OF THE SPECIAL GENERAL MEETING HELD ON 21 APRIL 2026

Reference is made to the circular of Meilleure Health International Industry Group Limited (the “**Company**”) dated 27 March 2026 (the “**Circular**”) and the notice of special general meeting of the same date (the “**Notice**”) in relation to the discloseable and connected transaction relating to the Equity Interest Transfer Agreement and the proposed adoption of the 2026 Share Award Scheme. Unless otherwise specified, capitalized terms used herein shall have the same meaning as those defined in the Circular.

POLL RESULT OF THE SGM

The Board is pleased to announce that the SGM was held at 11:00 a.m. on Tuesday, 21 April 2026 at Portion 2, 12/F, The Center, 99 Queen’s Road Central, Central, Hong Kong. At the SGM, a poll was demanded by the chairlady of the SGM for voting on all proposed resolutions as set out in the Notice.

The Board is pleased to announce that the proposed ordinary resolutions in relation to the discloseable and connected transaction relating to the Equity Interest Transfer Agreement and the proposed adoption of the 2026 Share Award Scheme (the “**Ordinary Resolutions**”) as set out in the Notice was duly passed by the Shareholders by way of poll at the SGM held on 21 April 2026.

As at the date of the SGM, the total number of issued shares of the Company was 4,088,428,636 Shares in issue (excluding treasury shares). As stated in the Circular, Mr. Zhou, Ms. Zhou and their respective will abstain from voting at the SGM with respect to the resolution approving the Equity Interest Transfer Agreement and the transactions contemplated thereunder. As at the date of the SGM, to the best knowledge of the Directors, Mr. Zhou, Ms. Zhou and their respective associates hold a total of 2,600,167,761 Shares,

representing approximately 63.60% of the issued share capital of the Company (excluding treasury shares) in aggregate. Save as disclosed above, no other Shareholder has a material interest in the transactions contemplated under the Equity Interest Transfer Agreement who would be required to abstain from voting on the resolutions to approve the Equity Interest Transfer Agreement and the transactions contemplated thereunder at the SGM.

Accordingly, the total number of Shares entitling the Independent Shareholders to attend and vote for or against the Ordinary Resolutions at the SGM was 1,488,260,875 Shares (representing approximately 36.40% of the issued share capital of the Company (excluding treasury shares) as at the date of the SGM). Save as disclosed above, (i) there were no Shares entitling the Independent Shareholders to attend and abstain from voting in favour of the Ordinary Resolutions at the SGM as set out in Rule 13.40 of the Listing Rules; (ii) no Shareholder was required under the Listing Rules to abstain from voting on the Ordinary Resolutions at the SGM; (iii) no Shareholder has stated his/her intention in the Circular to vote against or to abstain from voting on the Ordinary Resolutions at the SGM; and (iv) there were no restrictions on any shareholders to cast votes on any of the Ordinary Resolutions at the SGM.

The Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, was appointed as the scrutineer for the purpose of vote-taking at the SGM.

Mr. Zhou, Dr. Zeng Wentao, Ms. Zhou, Dr. Mao Zhenhua, Professor Chau Chi Wai, Wilton, Mr. Chen Shi and Mr. Wu Peng, being the Directors, attended the SGM.

The poll results of the Ordinary Resolutions are as follows:

Ordinary Resolutions		Number of votes (Approximately %)	
		For	Against
1.	(a) To approve, confirm and ratify the Equity Interest Transfer Agreement entered into by and among the Company and the Vendors, the terms and conditions thereof and the transactions contemplated thereunder.	131,073,997 (100%)	0 (0%)
	(b) To authorize any one or more of the Directors be and is/are hereby authorized to sign, seal, execute, perfect, deliver all such documents and to do all such things and acts as he/she/they may in his/her/their discretion consider necessary, expedient or desirable to effect the transactions contemplated under the Equity Interest Transfer Agreement, variation or modification of the terms and conditions of the Equity Interest Transfer Agreement upon such terms and conditions as he/she/they may think fit.	131,073,997 (100%)	0 (0%)

2.	(a) To approve and conditional upon the Listing Committee of the Stock Exchange granting approval for the listing of, and permission to deal in, the Shares which may fall to be issued pursuant to any Share Awards granted under the 2026 Share Award Scheme, the rules of which are contained in the document marked “A” produced to this meeting and signed by the chairman of this meeting for identification purpose, the 2026 Share Award Scheme be and is hereby approved and adopted, and any Director be and is hereby authorised to do all such acts and to enter into all such transactions, arrangements and agreements, for and on behalf of the Company, as he/ she/they may in his/her/their absolute discretion consider necessary, desirable or expedient in order to give effect to the 2026 Share Award Scheme.	2,682,204,288 (99.98%)	558,000 (0.02%)
	(b) To approve the total number of Shares which may be allotted and issued in respect of the Share Awards granted under the 2026 Share Award Scheme and any options or awards granted under any other share schemes of the Company must not in aggregate exceed 10% of the total number of Shares in issue as at the Effective Date.	2,682,204,288 (99.98%)	558,000 (0.02%)
3.	To approve conditional upon the passing of the ordinary resolution No. 2 set out above, the sublimit of 1% on the total number of Shares which may be allotted and issued in respect of the Share Awards granted under the 2026 Share Award Scheme, and any options or awards granted under any other share schemes of the Company to Service Providers (the “Service Provider Sublimit”) be and is hereby approved and adopted, and the Directors be and are hereby authorised to do all such acts and to enter into all such transactions, arrangements and agreements, for and on behalf of the Company, as he/she/they may in his/her/their absolute discretion consider necessary, desirable or expedient in order to give effect to the Service Provider Sublimit.	2,682,204,288 (99.98%)	558,000 (0.02%)

As more than 50% of the votes were cast in favour of resolutions numbered 1 to 3, all of these resolutions were duly passed as ordinary resolutions of the Company at the SGM.

By order of the Board
Meilleure Health International Industry Group Limited
Zhou Wen Chuan
Executive Director and Chief Executive Officer

Hong Kong, 21 April 2026

As at the date of this announcement, the Board comprises Mr. Zhou Xuzhou, Dr. Zeng Wentao and Ms. Zhou Wen Chuan as executive Directors, Dr. Mao Zhenhua as non-executive Director and Professor Chau Chi Wai, Wilton, Mr. Chen Shi and Mr. Wu Peng as independent non-executive Directors.